Last Update 02 Jul 26
Fair value Decreased 38%CERT: Peer Deal Premium Will Highlight Depressed Multiple Over Coming Years
Certara's updated analyst price target has decreased from $16.00 to $10.00 as analysts factor in lower modeled revenue growth and profit margins, while recent peer acquisition multiples support the view that the stock's valuation remains depressed relative to private market benchmarks.
Analyst Commentary
Recent commentary on Certara highlights a split view, with the headline price target reduction offset by some pointedly optimistic arguments about the stock's current valuation and business profile. While several firms have trimmed their targets, bullish analysts emphasize that Certara remains a profitable company operating in a niche where private market buyers appear willing to pay higher multiples.
The acquisition of peer Simulations Plus has become a key reference point in this discussion. Bullish analysts note that the roughly 90% premium implied by that deal, relative to their own 2027 EV/EBITDA framework for Certara, suggests a wide gap between where the stock trades and where private buyers are pricing similar assets. For investors, the comparison is being used as a reference for how public and private valuations can diverge for companies with similar business models.
Commentary also highlights Certara's margin profile and long-term growth drivers. Analysts point to what they describe as healthy EBITDA margins above 30% and to the company’s focus on model informed drug discovery as a core theme. The current period of investment under new leadership is being framed as an effort to support steadier revenue trends over time. This is presented as a strategic choice to reinforce the business, rather than a pivot away from profitability.
Even as target cuts from several houses reset expectations, the tone from bullish analysts is that recent deal activity in the sector offers an external check on how low Certara's trading multiple has fallen. The debate now centers on the company’s execution through this investment phase and how quickly it can translate its pipeline of opportunities into more consistent growth that could support a re-rating.
Bullish Takeaways
- Bullish analysts argue that the Simulations Plus acquisition premium, at roughly 90% above their 2027 EV/EBITDA framework for Certara, highlights how depressed the stock’s current valuation is compared with private market deals in similar businesses.
- Certara is still viewed as a highly profitable company, with commentary pointing to EBITDA margins above 30%, which some analysts see as a key support for the equity story even as revenue expectations are revised.
- There is a focus on long term growth drivers in model informed drug discovery, with the current investment period under new leadership framed as an effort to build a more consistent growth profile. This is seen as a continuation of margin discipline, rather than a step away from it.
- Bullish analysts suggest that recent sector M&A provides another data point for how the market values these assets privately. They see this as a potential catalyst if Certara delivers on its execution goals and narrows the gap between public and private valuation levels.
What's in the News for Certara
- Certara, Inc. was dropped from the Russell 1000 Index, Russell Midcap Index, Russell 1000 Value Benchmark, Russell Midcap Value Benchmark, and Russell 1000 Dynamic Index, and was added to the Russell 2000 Index, Russell 2000 Value Benchmark, and Russell 2000 Dynamic Index, reflecting a shift in its index classification.
- Certara launched Bio Venture Catalyst, an integrated offering aimed at helping emerging biotech companies assess opportunities, prioritize development decisions, manage risk, and present investor-ready development plans across pre-seed through Series B+ stages, using the company’s model informed drug development expertise. Source: Company announcement.
- Certara announced that Chief Financial Officer John E. Gallagher III tendered his resignation effective July 14, 2026. Senior Vice President, Finance and Treasurer Faiz Mohammed was appointed as Interim Chief Financial Officer effective July 15, 2026, while the company searches for a permanent successor. Source: Executive change filing.
- For full year 2026, Certara issued earnings guidance with revenue expected in a range of US$395 million to US$405 million, including approximately US$18 million from Regulatory and Medical Writing, and fully diluted shares projected at 157 million to 159 million. Source: Company guidance update.
- Certara reported that between January 1, 2026 and March 31, 2026, it repurchased 5,814,484 shares for US$39.89 million, completing a total of 9,182,858 shares repurchased for US$80.9 million under the buyback program announced on April 14, 2025. Source: Buyback tranche update.
- Certara entered into a partnership with Altasciences to combine Certara’s model informed drug development services and biosimulation technology with Altasciences’ Acceleration Platform. The partnership aims to help sponsors design more efficient early phase studies and make earlier go or no go decisions on drug candidates. Source: Joint partnership announcement.
Valuation Changes for Certara
- Fair Value: reduced from $16.00 to $10.00, a decline of roughly 37.5% in the updated framework for Certara.
- Discount Rate: adjusted slightly from 8.79% to 8.75%, indicating a small change in the assumed risk profile.
- Revenue Growth: lowered from 8.81% to 2.50%, reflecting a much more conservative view of Certara's forward revenue trajectory.
- Net Profit Margin: revised from 10.95% to 7.95%, pointing to a smaller expected earnings contribution from each dollar of revenue.
- Future P/E: moved from 54.15x to 50.45x, a modest reduction in the multiple applied to Certara's projected earnings.
Catalysts
About Certara
Certara provides biosimulation software and technology enabled services that help biopharma customers accelerate and de risk drug development.
What are the underlying business or industry changes driving this perspective?
- Rapid expansion of model informed drug development across discovery, preclinical and clinical phases, supported by FDA guidance on new approach methodologies and reduced animal use, should structurally increase demand for biosimulation software and QSP services. This could lift long term revenue growth and shift the mix toward higher margin offerings.
- Chemaxon integration and the build out of a unified discovery to development platform, combined with strong Simcyp growth and 104% software net retention, position Certara to capture larger enterprise wide footprints and wallet share. This supports the potential for sustained double digit software revenue growth and operating leverage.
- New cloud and AI enabled products such as Phoenix Cloud, Pinnacle 21 Enterprise and CertaraIQ create standardized, reusable models and workflows that scale globally. This should help drive recurring license uptake, expand subscription share and enhance gross margins and earnings power over time.
- Accelerating QSP demand in biologics, large molecules and complex modalities, together with foundational disease models that can be sold repeatedly, creates a high value, differentiated revenue stream that may outgrow the rest of the portfolio and support higher blended net margins.
- An improving mix toward software, disciplined cost management and productivity gains in services, plus lower interest expense from the term loan repricing and active share repurchases, collectively provide a multi year path for adjusted EBITDA margin expansion and potentially faster growth in adjusted EPS than in headline revenue.
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more optimistic perspective on Certara compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
- The bullish analysts are assuming Certara's revenue will grow by 2.5% annually over the next 3 years.
- The bullish analysts assume that profit margins will increase from -3.6% today to 8.0% in 3 years time.
- The bullish analysts expect earnings to reach $35.9 million (and earnings per share of $0.14) by about July 2029, up from -$15.1 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $-12.5 million.
- In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 50.6x on those 2029 earnings, up from -69.3x today. This future PE is greater than the current PE for the US Healthcare Services industry at 32.2x.
- The bullish analysts expect the number of shares outstanding to decline by 3.15% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 8.75%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- Persistent hesitancy and delayed decision-making among Tier 1 pharma customers in services, already driving only 1% bookings growth and a 9% decline in services bookings, could signal a structurally slower spending environment that caps long-term services revenue growth and constrains total company revenue.
- Organic growth remains modest at 3% to 4% over recent years and software organic revenue grew only 6% despite acquisitions and product launches, suggesting the core business may not naturally support the high single digit to double digit growth implied by a bullish view, which would limit long term earnings expansion.
- The regulatory services business has experienced inconsistent performance and double digit bookings declines while still being relied on for cash generation, so any divestiture or restructuring outcome from the ongoing strategic review could reduce cash flow support and weigh on net margins and earnings if not offset quickly by higher margin software growth.
- Chemaxon currently contributes a meaningful portion of software growth and is largely license based, so if its growth normalizes or customers shift away from upfront licenses, the mix driven gross margin tailwind could reverse and pressure overall gross margins and profitability.
- Heavy investment in R&D, up 24% year over year and now 10% of revenue, alongside aggressive AI and cloud product development may not translate into proportionate adoption if customers prioritize their own internal AI initiatives or slow spending cycles, which would compress the return on investment and limit future net margin and earnings improvement.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bullish price target for Certara is $10.0, which represents up to two standard deviations above the consensus price target of $7.48. This valuation is based on what can be assumed as the expectations of Certara's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $10.0, and the most bearish reporting a price target of just $6.0.
- In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $452.0 million, earnings will come to $35.9 million, and it would be trading on a PE ratio of 50.6x, assuming you use a discount rate of 8.7%.
- Given the current share price of $6.73, the analyst price target of $10.0 is 32.7% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Certara?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
